Detail akcie Shionogi & Co online

Business Summary: Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.
Financial Summary: BRIEF: For the fiscal year ended 31 March 2024, Shionogi & Co Ltd revenues increased 2% to Y435.08B. Net income decreased 12% to Y162.03B. Revenues reflect UK segment increase of 15% to Y201.29B, Americas excl. USA segment increase from Y6M to Y18.03B. Net income was offset by Dividends Income decrease of 43% to Y35.18B (income), Outsourcing expenses increase from Y8.18B to Y17.54B (expense).